<PAGE>

                                          
                         SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, D.C.  20549
                                          
                                     FORM 10-Q
                                            
                                            
                                            
/X/    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities 
       Exchange Act of 1934 for the Period Ended March 31, 1998.
                                            
                                         or
     
/ /    Transition Report Pursuant to Section 13 or 15(d) of the
       Securities Exchange Act of 1934 for the Transition Period From
       _____________ to __________________.
     
       Commission file number 0-27436        
                              -------
     
                            TITAN PHARMACEUTICALS, INC.
               (Exact name of registrant as specified in its charter)
                                          
                                          
                                          
                       DELAWARE                             94-3171940
                       --------                             ----------
            (State or Other Jurisdiction of               (I.R.S. Employer
            Incorporation or Organization)              Identification No.)
                                          
                                          
                                          
      400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080
      ------------------------------------------------------------------------
             (Address of Principal Executive Offices including zip code)
                                          
                                          
                                          
                                   (650) 244-4990
                                   --------------
                (Registrant's Telephone Number, Including Area Code)
                                          
                                          
     Indicate by check mark whether the Registrant (1) has filed all
     reports required to be filed by Section 13 or 15(d) of the Exchange
     Act during the preceding 12 months (or for such shorter period that
     the registrant was required to file such reports), and (2) has been
     subject to such filing requirements for the past 90 days.  Yes X   No
                                                                   ---     ---
     
     
     There were 13,100,883 shares of the Registrant's Common Stock issued and
     outstanding on May 11, 1998.
          
<PAGE>

                            TITAN PHARMACEUTICALS, INC.
                                 INDEX TO FORM 10-Q

                                          
                                          
PART I.   FINANCIAL INFORMATION                                         PAGE
                                                                        ----
     Item 1.  Condensed Financial Statements (unaudited)

     Condensed Consolidated Balance Sheets  
       March 31, 1998 and December 31, 1997. . . . . . . . . . . . . . . .2

     Condensed Consolidated Statements of Operations
       Three months ended March 31, 1998
       and 1997 and period from commencement of 
       operations (July 25, 1991) to March 31, 1998. . . . . . . . . . . .3

     Condensed Consolidated Statements of Cash Flows
       Three months ended March 31, 1998 and 1997 and
       period from commencement of operations 
       (July 25, 1991) to March 31, 1998 . . . . . . . . . . . . . . . . .4

     Notes to Condensed Consolidated Financial 
       Statements - March 31, 1998 . . . . . . . . . . . . . . . . . . . .6

     Item 2.  Management's Discussion and Analysis 
       or Plan of Operations . . . . . . . . . . . . . . . . . . . . . . .9

PART II.  OTHER INFORMATION

     Item 6.  Exhibits and Reports on Form 8-K . . . . . . . . . . . . . 11

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

<PAGE>

PART I.  FINANCIAL INFORMATION


                    TITAN PHARMACEUTICALS, INC.
                   (A DEVELOPMENT STAGE COMPANY)
               CONDENSED CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                   March 31,          December 31,
                                                                     1998                1997
                                                                  (unaudited)          (Note A)
                                                                  ------------        ------------
<S>                                                               <C>                 <C>
Assets
Current assets
     Cash and cash equivalents                                    $ 19,130,440        $ 24,386,872 
     Short-term investments                                            500,000             500,000 
     Prepaid expenses and other current assets                         121,900              58,937 
     Other receivables                                                     -               371,793 
                                                                  ------------        ------------
          Total current assets                                      19,752,340          25,317,602 
Furniture and equipment, net                                           269,980             253,723 
Other assets                                                            23,898              22,898 
                                                                  ------------        ------------
                                                                  $ 20,046,218        $ 25,594,223 
                                                                  ------------        ------------
                                                                  ------------        ------------
Liabilities and Stockholders' Equity 
Current Liabilities
     Accounts payable                                             $    859,497        $    815,449 
     Accrued legal fees                                                 50,906             244,486 
     Accrued sponsored research                                        124,312              65,500 
     Accrued payroll and related                                       161,902             257,751 
     Accrued professional and accounting fees                           64,500             100,000 
     Other accrued liabilities                                         120,000             192,487 
                                                                  ------------        ------------
          Total current liabilities                                  1,381,117           1,675,673 
Commitments
Minority interest - Series B preferred stock of Ingenex, Inc.        1,241,032           1,241,032 
Guaranteed security value (Note 2)                                         -             5,500,000 
Stockholders' Equity
     Preferred stock, at amounts paid in                             5,000,000           5,000,000 
     Common stock, at amounts paid in                               52,222,909          49,622,796 
     Additional paid-in capital                                      6,521,353           6,521,353 
     Deferred compensation                                            (415,400)           (458,340)
     Deficit accumulated during the development stage              (45,904,793)        (43,508,291)
                                                                  ------------        ------------
          Total stockholders' equity                                17,424,069          17,177,518 
                                                                  ------------        ------------
                                                                  $ 20,046,218        $ 25,594,223 
                                                                  ------------        ------------
                                                                  ------------        ------------
</TABLE>

          Note A:  The balance sheet at December 31, 1997 has been derived 
                   from the audited financial statements at that date but 
                   does not include all of the information and footnotes 
                   required by generally accepted accounting principles for 
                   complete financial statements.


          See Notes to Condensed Consolidated Financial Statements


                                       2
<PAGE>

                    TITAN PHARMACEUTICALS, INC.
                   (A DEVELOPMENT STAGE COMPANY)
         CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                           (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                                   COMMENCEMENT
                                                                                                   OF OPERATIONS
                                                                 THREE MONTHS ENDED MARCH 31,      (JULY 25, 1991) 
                                                                 ---------------------------             TO
                                                                     1998           1997           MARCH 31, 1998
                                                                 ------------   ------------       --------------
<S>                                                             <C>             <C>                 <C>
License and grant revenue                                       $       -       $     36,262        $ 17,898,281 

Costs and expenses:                                              
     Research and development                                     1,686,240        2,174,735          38,576,556 
     Acquired in-process research and development                       -          9,500,000          10,186,000 
     General and administrative                                   1,029,620        1,336,918          19,371,569 
                                                                -----------     ------------        ------------
          Total costs and expenses                                2,715,860       13,011,653          68,134,125 
                                                                -----------     ------------        ------------
          Loss from operations                                   (2,715,860)     (12,975,391)        (50,235,844)

Other income (expense):                                          
     Equity in loss of Ansan Pharmaceuticals, Inc.                      -           (280,039)         (2,046,939)
     Gain on sale of technology                                         -                -             8,361,220 
     Interest income                                                263,819          171,935           2,100,980 
     Interest expense                                                   (87)         (75,071)         (4,389,774)
     Other income (expense)                                          55,626              -               260,650 
                                                                -----------     ------------        ------------
         Other income (expense) - net                               319,358         (183,175)          4,286,137 
                                                                -----------     ------------        ------------
Loss before minority interest                                    (2,396,502)     (13,158,566)        (45,949,707)

Minority interest in losses of subsidiaries                             -                -                44,914 

Net loss                                                        $(2,396,502)    $(13,158,566)       $(45,904,793)

Deemed dividend upon conversion of preferred stock                      -                -            (5,431,871)
                                                                -----------     ------------        ------------
     
Net loss attributable to common stockholders                    $(2,396,502)    $(13,158,566)       $(51,336,664)
                                                                -----------     ------------        ------------
                                                                -----------     ------------        ------------
     
Basic and diluted net loss per common share                     $     (0.18)    $      (1.02)
                                                                -----------     ------------
                                                                -----------     ------------
     
Shares used in computing basic and diluted net loss per share    13,078,801       12,897,703 
                                                                -----------     ------------
                                                                -----------     ------------
</TABLE>


          See Notes to Condensed Consolidated Financial Statements


                                      3
<PAGE>

                    TITAN PHARMACEUTICALS, INC.
                   (A DEVELOPMENT STAGE COMPANY)
           CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                                         PERIOD FROM
                                                                                                         COMMENCEMENT
                                                                  THREE MONTHS ENDED MARCH 31,           OF OPERATIONS
                                                                --------------------------------      (JULY 25, 1991) TO
                                                                    1998               1997              MARCH 31, 1998
                                                                -----------        ------------       ------------------
<S>                                                             <C>                <C>                   <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss                                                        $(2,396,502)       $(13,158,566)         $(45,904,793)
Adjustments to reconcile net loss to net cash used               
  in operating activities:                                       
   Depreciation and amortization expense                             70,580             143,210             1,519,274 
   Issuance of common stock to acquire technology                       -             5,500,000             5,500,000 
   Payment of guaranteed security value                          (3,044,409)                -              (3,044,409)
   Accretion of discount on indebtedness                                -                   -               2,290,910 
   Equity in loss of Ansan Pharmaceuticals, Inc.                        -               280,039             2,046,940 
   Other                                                                -                   -                 (35,653)
   Issuance of common stock to acquire                           
     minority interest of Theracell, Inc.                               -                   -                 686,000 
   Changes in operating assets and liabilities:                  
     Prepaid expenses and other current assets                      (62,963)            (20,431)             (121,900)
     Receivable from Ansan Pharmaceuticals, Inc.                        -               (19,034)                  -   
     Other receivables                                              371,793                 -                     -   
     Other assets                                                    (1,000)            (80,262)              (28,863)
     Accounts payable                                                44,048              13,764             1,183,687 
     Accrued license fee                                                -             2,000,000
     Other accrued liabilities                                     (338,604)             57,025               922,036 
                                                                -----------        ------------          ------------
Net cash used in operating activities                            (5,357,057)         (5,284,255)          (34,986,771)
                                                                -----------        ------------          ------------
                                                                                                         
CASH FLOWS FROM INVESTING ACTIVITIES                              
Purchase of furniture and equipment                                 (43,897)            (32,111)           (1,195,120)
Purchase of short-term investments                                      -              (100,000)          (59,782,493)
Proceeds from sale of short-term investments                            -             8,600,000            59,282,493 
Issuance of debenture to Ansan                                   
    Pharmaceuticals, Inc.                                               -            (1,000,000)       
Effect of deconsolidation of                                     
    Ansan Pharmaceuticals, Inc.                                         -                   -                (135,934)
                                                                -----------        ------------          ------------
Net cash (used in)/provided by investing activities                 (43,897)          7,467,889            (1,831,054)
                                                                -----------        ------------          ------------
                                                                                                         
</TABLE>


          See Notes to Condensed Consolidated Financial Statements


                                     4
<PAGE>

                    TITAN PHARMACEUTICALS, INC.
                   (A DEVELOPMENT STAGE COMPANY)
         CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                                         PERIOD FROM
                                                                                                         COMMENCEMENT
                                                                  THREE MONTHS ENDED MARCH 31,           OF OPERATIONS
                                                                --------------------------------      (JULY 25, 1991) TO
                                                                    1998               1997              MARCH 31, 1998
                                                                -----------        ------------       ------------------
<S>                                                             <C>                <C>                   <C>
CASH FLOWS FROM FINANCING ACTIVITIES                              
Issuance of common stock                                        $   144,522        $      2,998          $ 30,173,296 
Deferred financing costs                                                -                   -                (713,899)
Issuance of preferred stock                                             -                   -              17,601,443 
Issuance of preferred stock - Novartis                                  -                   -               5,000,000 
Proceeds from notes and advances payable                                -                   -               2,681,500 
Repayment of notes payable                                              -                   -              (1,441,500)
Proceeds from Ansan bridge financing                                    -                   -               1,425,000 
Proceeds from Titan Pharmaceuticals, Inc. and                    
    Ingenex, Inc. bridge financing                                      -                   -               5,250,000 
Repayment of Titan Pharmaceuticals, Inc. and                     
    Ingenex, Inc. bridge financing                                      -                   -              (5,250,000)
Payments of principle under capital lease obligation                    -               (62,494)             (633,766)
Proceeds from capital lease bridge financing                            -                   -                 658,206 
Proceeds from Ingenex, Inc. technology financing                        -                   -               2,000,000 
Principal payments on Ingenex, Inc. technology financing                -              (135,061)           (2,000,000)
Increase in minority interest from issuances of                  
    preferred stock by Ingenex, Inc.                                    -                   -               1,241,032 
Issuance of common stock by subsidiaries                                -                   -                 173,652 
Loss on disposal of assets                                              -                   -                (216,699)
                                                                -----------        ------------          ------------
Net cash provided by/(used in) financing activities                 144,522            (194,557)           55,948,265
                                                                -----------        ------------          ------------

Net (decrease)/increase in cash and cash equivalents             (5,256,432)          1,989,077            19,130,440
Cash and cash equivalents, beginning of period                   24,386,872           1,376,532                 -   
                                                                -----------        ------------          ------------
Cash and cash equivalents, end of period                        $19,130,440        $  3,365,609          $ 19,130,440 
                                                                -----------        ------------          ------------
                                                                -----------        ------------          ------------

Supplemental cash flow disclosure                                
Interest paid                                                   $        87        $     75,071          $  1,393,396 
                                                                -----------        ------------          ------------
                                                                -----------        ------------          ------------
</TABLE>


          See Notes to Condensed Consolidated Financial Statements


                                     5
<PAGE>

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

THE COMPANY AND ITS SEVERAL DEVELOPMENT STAGE SUBSIDIARIES

     Titan Pharmaceuticals, Inc. (the "Company" or "Titan"), was 
incorporated in February 1992 in the State of Delaware.  Titan is a 
biopharmaceutical company developing proprietary therapeutics for the 
treatment of central nervous system disorders, cancer and other serious and 
life-threatening diseases. Titan conducts a portion of its operations through 
three development stage biotechnology companies: Ingenex, Inc. ("Ingenex"), 
Theracell, Inc. ("Theracell") and ProNeura, Inc. ("ProNeura"), collectively, 
(the "Operating Companies"). Trilex Pharmaceuticals, Inc. ("Trilex") was 
incorporated in May 1996, as a wholly-owned subsidiary of the Company, to 
engage in the development of cancer therapeutic vaccines utilizing 
anti-idiotypic antibody technology.  In August 1997, Trilex was merged (the 
"Trilex Merger") with and into Titan.

     INGENEX, INC.

     Ingenex is engaged in the development of gene-based therapeutics and the 
discovery of medically important genes for the treatment of cancer and viral 
diseases.  In September 1994, Ingenex issued shares of its Series B 
convertible preferred stock to a third party for $1,241,032, net of issuance 
costs.  In June 1996, Ingenex issued 981,818 shares of common stock to the 
Company, converting $5,400,000 of debt payable. Also in June 1996, and in 
consideration of a payment to Ingenex of $100,000, Ingenex issued to the 
Company an option to purchase an additional 315,789 shares of common stock 
which will have an exercise price per share equal to the initial public 
offering price of Ingenex common stock and an additional option and a right 
of first refusal with respect to future issuances of common stock in order 
for the Company to maintain ownership of a majority of the outstanding common 
stock.  The option expires one year from the date of the consummation of the 
initial public offering of Ingenex common stock.  In June 1997, Ingenex sold 
its GSX System (the "GSX Sale"), a research technology, and certain fixed 
assets to Pharmaceutical Product Development, Inc. ("PPD") for $8,722,500 in 
cash and the assumption of certain capital lease liabilities and recognized a 
gain of $8,361,220.  At March 31, 1998, the Company owned 81% of Ingenex, 
assuming the conversion of all preferred stock to common.

     THERACELL, INC.

     Theracell was incorporated in November 1992 to engage in the development 
of novel treatments for various neurologic disorders through the 
transplantation of neural cells and neuron-like cells directly into the 
brain.  The Company's ownership in Theracell was 85% through November 1995, 
at which time the Company entered into an agreement with the minority 
stockholders of Theracell pursuant to which 140,000 shares of the Company's 
stock were issued in exchange for all the outstanding shares of Theracell 
common stock held by them.  In connection with the issuance of the 140,000 
shares, the Company recorded a charge for acquired in-process research and 
development of $686,000.  In November 1995, the former minority stockholders 
of Theracell were granted an option to acquire 5% of the issued and 
outstanding capital stock of Theracell.  These options can be exercised at a 
price of $1.59 per share within a period of three years from January 18, 
1996.  Commencing thirty days after the date Theracell's shares are first 
publicly traded, the Theracell options may be subject to redemption under 
certain conditions by Theracell on thirty days' written notice at a 
redemption price of $0.05 per share if the closing price of Theracell's 
common stock for any thirty consecutive trading days ending within fifteen 
days of the notice of redemption averages in excess of $3.18 per share.  At 
March 31, 1998, the Company owned 98% of Theracell.

     PRONEURA, INC.

     ProNeura was incorporated in October 1995 to engage in the development 
of cost effective, long term treatment solutions to neurologic and 
psychiatric disorders through an implantable drug delivery system.  At March 
31, 1998, the Company owned 79% of ProNeura.
  

                                      6
<PAGE>

     BASIS OF PRESENTATION

     The accompanying unaudited condensed consolidated financial statements 
include the accounts of Titan and its majority owned subsidiaries after 
elimination of all significant intercompany accounts and transactions.  These 
financial statements have been prepared in accordance with generally accepted 
accounting principles for interim financial information and with the 
instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, 
they do not include all of the information and footnotes required by 
generally accepted accounting principles for complete financial statements.  
In the opinion of management, all adjustments (consisting of normal recurring 
accruals) considered necessary for a fair presentation have been included.  
Operating results for the three-month period ended March 31, 1998 are not 
necessarily indicative of the results that may be expected for the year ended 
December 31, 1998.  These financials should be read in conjunction with the 
audited consolidated financial statements and footnotes thereto included in 
the Titan Pharmaceuticals, Inc. annual report on Form 10-K for the year ended 
December 31, 1997.

2. GUARANTEED SECURITY VALUE

In January 1997, the Company entered into an exclusive license agreement with 
Hoechst Marion Roussel, Inc. ("HMRI").  The license agreement gave the 
Company a worldwide license to HMRI's patent rights and know-how related to 
the antipsychotic agent Iloperidone-TM-.  Pursuant to the license, the 
Company paid, during 1997, an up-front license fee of $9,500,000, consisting 
of:  (i) $4,000,000 in cash and (ii) $5,500,000 through the issuance 594,595 
shares of common stock (the "HMRI Shares".)  The Company was obligated to pay 
to HMRI the difference between $5,500,000 and the net proceeds received by 
HMRI upon sale of the above mentioned common stock.  Accordingly, the Company 
had classified the entire $5,500,000 as a non-current liability under the 
heading Guaranteed Security Value in the accompanying December 31, 1997 
balance sheet. In February 1998, HMRI sold the HMRI Shares for net proceeds 
of approximately $2,456,000. Accordingly, in March 1998, the Company paid to 
HMRI approximately $3,044,000, which was deducted from Guaranteed Security 
Value balance.  The remaining balance of $2,456,000 was transferred to 
stockholders' equity.

3. CHANGES IN ACCOUNTING STANDARDS

As of January 1, 1998, the Company adopted Statement of Financial Accounting 
Standards No. 130, "Reporting Comprehensive Income" ("SFAS No. 130").  SFAS 
No. 130 establishes new rules for the reporting and display of comprehensive 
income and its components; however, the adoption of this statement has no 
impact on the Company's net loss or stockholders' equity.  During the three 
months ended March 31, 1998 and 1997, the Company's comprehensive loss was 
the same as the Company's net loss for such periods. 


                                      7
<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

     The following discussion contains certain forward-looking statements, 
within the meaning of the "safe harbor" provisions of the Private Securities 
Litigation Reform Act of 1995, the attainment of which involves various risks 
and uncertainties.  Forward-looking statements may be identified by the use 
of forward-looking terminology such as "may," "will," "expect," "believe," 
"estimate," "anticipate," "continue" or similar terms, variations of those 
terms or the negative of those terms.  The Company's actual results may 
differ materially from those described in these forward-looking statements 
due to, among other factors, the results of ongoing research and development 
activities and preclinical testing, the results of clinical trials and the 
availability of additional financing through corporate partnering 
arrangements or otherwise.

RESULTS OF OPERATIONS

     Since its inception, the Company's efforts have been principally devoted 
to acquiring technologies, research, clinical development, securing patent 
protection and raising capital.  At March 31, 1998, the Company had an 
accumulated deficit of approximately $45,905,000, resulting from expenditures 
for research and development and general and administrative activities 
including professional fees.

     There were no revenues for the three months ended March 31, 1998 ("1998 
quarter") and approximately $36,000 for the three months ended March 31, 1997 
("1997 quarter") from government grants. 

     Research and development expenses for the 1998 quarter were 
approximately $1,686,000 compared with $2,175,000 for the 1997 quarter, a 
decrease of 22%. The 1997 quarter includes development of the GSX technology, 
which was subsequently sold by the Company in June 1997.  The results for the 
1997 quarter also include a non-recurring, acquired in-process research and 
development charge of $9,500,000 related to the acquisition of Iloperidone.

     General and administrative expenses for the 1998 quarter were 
approximately $1,030,000 compared with $1,337,000 for the 1997 quarter, a 
decrease of 23%. The 1997 quarter includes expenditures related to Trilex 
Pharmaceuticals, which was merged with and into the Company in August 1997, 
reducing general and administrative expenses.

     Other income for the 1998 quarter was approximately $319,000 compared to 
an expense of approximately $183,000 for the 1997 quarter, a net change of 
approximately $503,000.  Other income for the 1998 quarter includes interest 
income of approximately $264,000 compared to $172,000 during the 1997 
quarter. Interest expense for the 1997 quarter was approximately $75,000, 
which was attributable to a capital equipment lease and a technology 
financing agreement, both of which were retired with proceeds of the GSX 
sale.  Other income for the 1997 quarter also includes losses of 
approximately $280,000 representing the Company's share of Ansan 
Pharmaceutical's losses.

LIQUIDITY AND SOURCES OF CAPITAL

     The Company has funded its operation from inception primarily through 
private placements of its securities, as well as the IPO.  During 1997, the 
Company also received approximately $25,861,000 from up-front license fees  
relating to the sublicense of Iloperidone to Novartis Pharma AG and the GSX 
sale.

     In March 1998, the Company paid to HMRI approximately $3,044,000 (the 
difference between the net proceeds received by HMRI, upon the sale of the 
HMRI Shares in February 1998, and the $5,500,000 guaranteed value of the HMRI 
Shares when issued.)  As the Company classified the $5,500,000 as guaranteed 
security value, the HMRI Shares had not been included in stockholders' 
equity.  Upon the payment to HMRI, approximately $2,456,000 was credited to 
stockholders' equity.


                                      8
<PAGE>

     Titan has entered into various agreements with research institutions, 
universities, and other entities for the performance of research and 
development activities and for the acquisition of licenses related to those 
activities.  The aggregate commitments the Company has under these 
agreements, including minimum license payments, for the next 12 months is 
approximately $1,319,000.  Certain of the licenses provide for the payment of 
royalties by the Company on future product sales, if any.  In addition, in 
order to maintain license and other rights while products are under 
development, the Company must comply with customary licensee obligations, 
including the payment of patent related costs and meeting project-funding 
milestones.

     The Company expects to continue to incur substantial additional 
operating losses from costs related to continuation and expansion of research 
and development, clinical trials, and increased administrative and fund 
raising activities over at least the next several years.  While the Company 
has sufficient working capital to sustain planned operations for a period 
greater than 12 months, the Company may seek additional financing sooner, 
depending on numerous factors including, but not limited to, the progress of 
the Company's research and development programs, the results of clinical 
studies, technological advances, determinations as to the commercial 
potential of the Company's products, and the status of competitive products. 
The Company is currently negotiating a $5,000,000 bank line of credit.  In 
addition, certain expenditures will be dependent on the establishment of 
collaborative relationships with other companies, the availability of 
financing, and other factors.  In any event, the Company anticipates that it 
will require substantial additional financing in the future.  There can be no 
assurance as to the availability or terms of any required additional 
financing, when and if needed.

                                        9
<PAGE>
                                      PART II

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         (a)  Exhibits
              27.1           Financial Data Schedule


         (b)  Reports on Form 8-K
              No reports on Form 8-K were filed during the three months ended
              March 31, 1998.


                                     10
<PAGE>

                                 SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant 
caused this report to be signed on its behalf by the undersigned, thereunto 
duly authorized.
   

                                TITAN PHARMACEUTICALS, INC.

          May 14, 1998          By: /s/ Louis R. Bucalo
                                    ------------------------------------------
                                    Louis R. Bucalo, M.D., President and 
                                    Chief Executive Officer

          May 14, 1998          By: /s/ Robert E. Farrell
                                    ------------------------------------------
                                    Robert E. Farrell, Chief Financial Officer


                                     11